Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Amazon Explores AI Content Marketplace With Media Publishers 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SEATTLE, April 05, 2018 -- According to Coherent Market Insights, the global disease control and prevention vaccine market was valued US$ 41.12 Billion in 2017 and is projected to exhibit a CAGR of 12.1% over the forecast period (2017 – 2025).
To know the latest trends and insights prevalent in this market, click the link below: https://www.coherentmarketinsights.com/market-insight/disease-control-and-prevention-vaccine-market-1500
Key Trends and Analysis of the Disease Control and Prevention Vaccine Market:
Increasing research and development activities by manufacturers for introducing new vaccines is expected to drive growth of the market. For instance, in 2014, National Institute of Allergy and Infectious Disease, department of National institute of Health (NIH) collaborating with GlaxoSmithKline developed Ebola vaccine, which is in clinical trial phase in the U.K. Moreover, development of HIV vaccine is major target of vaccine developing companies and institutes, which is expected to be launched over the forecast period, which in turn is expected to drive growth of the disease control and prevention vaccine market. For instance, Johnson & Johnson together with a consortium of global partners initiated the first efficacy study for an investigational mosaic HIV-1 preventive vaccine. Such novel vaccines launches are expected to boost growth of disease control and prevention vaccines market over the forecast period.
Inovio’s HIV vaccine studies are supported by HIV Vaccine Trails Network (HVTN) and NIH’s National Institute of Allergy and Infectious Disease (NIAID). The studies received financial support of US$ 25 million in 2009, followed by US$ 16 million for five year from NIAID. Furthermore, manufacturers of vaccine market are continuously updating their product portfolio by adopting advance research and development strategies.
Request Sample Copy of this Report
Key Market Takeaways:
- Disease control and prevention vaccine market is projected to witness CAGR of 12.1% during the forecast period (2017–2025), owing to increasing vaccination programs by the government to eradicate disease
- High prevalence of infectious disease is expected to propel demand for infectious disease vaccine in the disease control and prevention vaccine market
- Major players operating in the global disease control and prevention vaccine market include GlaxoSmithKline plc (GSK), Merck & Co. Inc., Sanofi, AstraZeneca PLC, Pfizer, Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Astellas Pharma Inc., and Daiichi Sankyo
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
